Cas No.: | 439239-92-6 |
Chemical Name: | Lasmiditan hemisuccinate |
Synonyms: | butanedioic acid,2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl]benzamide;LASMIDITAN SUCCINATE;Lasmiditan hemisuccinate;W64YBJ346B;LY683974;2,4,6-Trifluoro-N-(6-((1-methylpiperidine-4-yl)carbonyl)pyridin-2-yl)benzamide succinic (2:1);Lasmiditan succinate [USAN];Reyvow (TN);Lasmiditan succinate (JAN/USAN);s6489;D10424;Q27292373;2,4,6-Trifluoro-N-(6-((1-methylpiperidine-4-yl)carbonyl)pyridin-2-yl)benzamide hemisuccinate;Butanedioic acid, compd. with 2,4,6-trifluoro-N-(6-(( |
SMILES: | FC1C=C(C=C(C=1C(NC1=CC=CC(C(C2CCN(C)CC2)=O)=N1)=O)F)F.FC1C=C(C=C(C=1C(NC1=CC=CC(C(C2CCN(C)CC2)=O)=N1)=O)F)F.OC(CCC(=O)O)=O |
Formula: | C42H42F6N6O8 |
M.Wt: | 872.808711528778 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Lasmiditan, also known as COL-144 and LY573144, is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist (K1=2.21 μM) without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. Lasmiditan showed efficacy in its primary endpoint, with a 2-hour placebo-subtracted headache response of 28.8%, though with frequent reports of dizziness, paresthesias, and vertigo. |